Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Lynn Morris

Evolution of an HIV Glycan–dependent Broadly Neutralizing Antibody Epitope Through Immune Escape

Nature Medicine

English

Reactivity of Routine HIV Antibody Tests in Children Who Initiated Antiretroviral Therapy in Early Infancy as Part of the Children With HIV Early Antiretroviral Therapy (CHER) Trial: A Retrospective Analysis

The Lancet Infectious Diseases

Infectious Diseases

2015

English

Switching Children Previously Exposed to Nevirapine to Nevirapine-Based Treatment After Initial Suppression With a Protease-Inhibitor-Based Regimen: Long-Term Follow-Up of a Randomised, Open-Label Trial

The Lancet Infectious Diseases

Infectious Diseases

2012

English

Reuse of Nevirapine in Exposed HIV-Infected Children After Protease Inhibitor–Based Viral Suppression

JAMA - Journal of the American Medical Association

Medicine

2010

English

Phenotypic Deficits in the HIV-1 Envelope Are Associated With the Maturation of a V2-Directed Broadly Neutralizing Antibody Lineage

English

Select Gp120 V2 Domain Specific Antibodies Derived From HIV and SIV Infection and Vaccination Inhibit Gp120 Binding to Α4β7

English

Correction: Features of Recently Transmitted HIV-1 Clade C Viruses That Impact Antibody Recognition: Implications for Active and Passive Immunization

English

HIV-1 Drug Resistance at Antiretroviral Treatment Initiation in Children Previously Exposed to Single-Dose Nevirapine

English

Population-Based Surveillance of HIV Drug Resistance Emerging on Treatment and Associated Factors at Sentinel Antiretroviral Therapy Sites in Namibia

Journal of Acquired Immune Deficiency Syndromes

Infectious Diseases

Pharmacology

2015

English

Decay of K103N Mutants in Cellular DNA and Plasma RNA After Single-Dose Nevirapine to Reduce Mother-To-Child HIV Transmission

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Lynn Morris

Evolution of an HIV Glycan–dependent Broadly Neutralizing Antibody Epitope Through Immune Escape

Reactivity of Routine HIV Antibody Tests in Children Who Initiated Antiretroviral Therapy in Early Infancy as Part of the Children With HIV Early Antiretroviral Therapy (CHER) Trial: A Retrospective Analysis

Switching Children Previously Exposed to Nevirapine to Nevirapine-Based Treatment After Initial Suppression With a Protease-Inhibitor-Based Regimen: Long-Term Follow-Up of a Randomised, Open-Label Trial

Reuse of Nevirapine in Exposed HIV-Infected Children After Protease Inhibitor–Based Viral Suppression

Phenotypic Deficits in the HIV-1 Envelope Are Associated With the Maturation of a V2-Directed Broadly Neutralizing Antibody Lineage

Select Gp120 V2 Domain Specific Antibodies Derived From HIV and SIV Infection and Vaccination Inhibit Gp120 Binding to Α4β7

Correction: Features of Recently Transmitted HIV-1 Clade C Viruses That Impact Antibody Recognition: Implications for Active and Passive Immunization

HIV-1 Drug Resistance at Antiretroviral Treatment Initiation in Children Previously Exposed to Single-Dose Nevirapine

Population-Based Surveillance of HIV Drug Resistance Emerging on Treatment and Associated Factors at Sentinel Antiretroviral Therapy Sites in Namibia

Decay of K103N Mutants in Cellular DNA and Plasma RNA After Single-Dose Nevirapine to Reduce Mother-To-Child HIV Transmission